Bellicum Pharmaceuticals (BLCM) Stock: Gaining On Clinical Update

Bellicum Pharmaceuticals Inc BLCM Stock News

Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) is having an overwhelmingly positive day in the market today, and for good reason. The company announced an update with regard to a clinical hold that’s leading to excitement among investors. Today, we’ll talk about the update, what we’re seeing from the stock, and what we’ll be watching for ahead.

BLCM Announces Update About Clinical Hold

As mentioned above, Bellicum Pharmaceuticals is having a strong day in the market today after announcing that it has received a notification from the United States Food and Drug Administration (FDA). In a press release issued early this morning, the company announced that the FDA has outlined criteria required for lifting the clinical hold on U.S. studies of BPX-501.

In the release, BLCM said that it plans to implement revisions to the U.S. study protocols, including the addition of more comprehensive monitoring and management neurotoxicity. Finally, the company said that it will revise the Investigator Brochure and Informed Consent Documents to inform healthcare providers, patients and caregivers of the changes. In the release, BLCM said that it expects to provide a full response to the FDA within a few weeks. Also, the company reminded investors that the clinical hold does not affect the Company’s BP-004 registration trial in Europe.




What We’re Seeing From The Stock 

One of the first lessons that we learn when we start to dabble in the market is that the news causes moves. In this particular case, the company now has a road map with regard to what it needs to do in order seek regulatory approval for BP-004. So, it’s no surprise to see that the stock is gaining in the market today. Currently (10:08), BLCM is trading at $7.39 per share after a gain of $0.72 per share or 10.86% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on BLCM. In particular, we’re interested in following the company as it works to bring BPX-501 to market. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!
* indicates required


Add Comment